Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579028 | 0.83 | ALDH1A1 (0.52) | ALDH1A1ALOX15KDM4CKDM4ETDP1 | |
| SCHEMBL82604 | 0.81 | KDM4C (0.59) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| SCHEMBL29578794 | 0.81 | KDM4C (0.59) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| SCHEMBL2265522 | 0.80 | KDM4C (0.47) | ALDH1A1ALOX15KDM4CKDM4ETDP1 | |
| SCHEMBL25201864 | 0.79 | KDM4C (0.42) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1027857 | 0.79 | KDM4C (0.57) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| SCHEMBL30298673 | 0.79 | TDP1 (0.55) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| SCHEMBL459712 | 0.79 | LOXL2 (0.44) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| SCHEMBL2618803 | 0.79 | TDP1 (0.55) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 | |
| SCHEMBL20819380 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KDM4CKDM4ETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071437-B1 | Pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-2-carboxylic acids as CK2 inhibitors | King Faisal University (SA) | 2024-08-27 | — | — | US | disclosed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| US-12012406-B1 | Pyrido[4,3-e]pyrrolo[1,2-a]pyrimidine as CK2 inhibitors | King Faisal University (SA) | 2024-06-18 | — | — | US | disclosed |
| US-12012414-B1 | Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors | King Faisal University (SA) | 2024-06-18 | — | — | US | disclosed |
| US-12012407-B1 | Pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acids as CK2 inhibitors | King Faisal University (SA) | 2024-06-18 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-114591311-A | Compounds that modulate intracellular calcium | 钙医学公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3426638-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2020-05-06 | — | — | EP | disclosed |
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1848435-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2007087443-A2 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006081391-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
| EP-0878196-B1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6133258-A | PYRIDOTHIAZINE DERIVATIVE; FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS, PAIN, GLAUCOMA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0878196-A1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012407-B1 | Pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acids as CK2 inhibitors | CDK2, PDXK, CSNK2A3 | ALDH1A1 3301/4885ALOX15 2586/4885KDM4C 2612/4885 |
| US-12012406-B1 | Pyrido[4,3-e]pyrrolo[1,2-a]pyrimidine as CK2 inhibitors | CDK2, PDXK, SKP2 | ALDH1A1 3997/4885ALOX15 2745/4885KDM4C 2377/4885 |
| US-12071437-B1 | Pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-2-carboxylic acids as CK2 inhibitors | CDK2, PDXK, SKP2 | ALDH1A1 3228/4885ALOX15 2535/4885KDM4C 2687/4885 |
| US-10336738-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | ALDH1A1 4409/4885ALOX15 1014/4885KDM4C 4521/4885 |
| US-12012414-B1 | Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors | CDK2, CSNK1A1, CSNK2A1 | ALDH1A1 3763/4885ALOX15 3384/4885KDM4C 2322/4885 |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | IL4, IL5, IL2 | ALDH1A1 2396/4885ALOX15 2664/4885KDM4C 697/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ALDH1A1 2794/4885ALOX15 4334/4885KDM4C 3114/4885 |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, IL5, NAT1 | ALDH1A1 2181/4885ALOX15 2805/4885KDM4C 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.